Biliary atresia is an uncommon disorder that mostly affects children. The bile ducts that convey bile from the liver to the gall bladder become obstructed in this syndrome. About two to eight weeks after delivery, symptoms of this condition begin. Jaundice, pale-colored feces, slow or no weight gain, dark urine, and an enlarged spleen are all symptoms of biliary atresia. When biliary atresia is suspected, a procedure known as a Kasai portoenterostomy must be performed as soon as possible, because an early operation is more likely to be effective. If the Kasai procedure fails, a liver transplant may be required.
During the forecast period, the market is expected to rise due to the rising prevalence of biliary atresia and its treatment.
During the forecast period, the market is expected to expand due to the rising incidence of the Biliary Atresia Treatment Market. According to a March 2016 study published by Research Gate, the Taiwan National Health Insurance Research Database was used to identify kids born with biliary atresia between 1997 and 2010. Furthermore, out of 513 total biliary atresia cases, 457 (89 percent) had surgery (Kasai procedure).
During the forecast period, the market is expected to rise due to developments in laboratory screening and diagnosis of biliary atresia.
The biliary atresia treatment market is predicted to increase due to rising breakthroughs in laboratory screening and diagnosis of biliary atresia by researchers and key players over the forecast period. Recent advancements in non-invasive molecular markers, such as gamma-glutamyl transpeptidase (GGT), matrix metalloproteinase-7 (MMP7), interleukin-33 (IL-33), and stool proteomics, have shown promising results as effective diagnostic markers in biliary atresia, according to an article published in the journal 'Digestive Medical Research' in September 2021.
Players to Watch
AstraZeneca plc, Eisai Co., Ltd., Mirum Pharmaceuticals, Inc., Pfizer Inc., Albireo Pharma, Inc., Novartis AG, Alkem Labs, and Glenmark Pharmaceuticals are among the major competitors in the global biliary atresia treatment market.
0 Comments